

Amendments to the Claims:

1. (withdrawn) A method of measuring expression of a cell-surface molecule on the surface of human blood cells, comprising:

contacting a sample containing human blood cells with a lysosomotropic amine and an antibody specific for said cell-surface molecule; and then detecting the binding of said antibody to said cells.

2. (withdrawn) The method of claim 1, wherein said sample is unfractionated peripheral blood.

3. (withdrawn) The method of claim 1, wherein said lysosomotropic amine is selected from the group consisting of chloroquine, hydroxychloroquine, primaquine, and methylamine.

4. (withdrawn) The method of claim 3, wherein said lysosomotropic amine is chloroquine.

5. (withdrawn) The method of claim 3, wherein said lysosomotropic amine is hydroxychloroquine.

6. (withdrawn) The method of claim 1, wherein said antibody is labeled with a fluorophore.

7. (withdrawn) The method of claim 6, wherein said fluorophore is selected from the group consisting of PE, APC, FITC, and PerCP.

8. (withdrawn) The method of claim 7, wherein said fluorophore is PE.

9. (withdrawn) The method of claim 8, wherein said fluorophore is conjugated to said antibody at a defined molar ratio.

10. (withdrawn) The method of claim 9, wherein said ratio is 1:1.

11. (withdrawn) The method of claim 1, wherein said antibody binding is detected flow cytometrically.

12. (withdrawn) The method of claim 11, wherein said lysosomotropic amine is chloroquine and said antibody is conjugated to PE.

13. (withdrawn) The method of claim 12, wherein said antibody is conjugated to PE at a molar ratio of 1:1.

14-24. (canceled)

25. (withdrawn) The method of claim 2, further comprising the step, after said contacting step and before said detecting step, of: lysing the erythrocytes in said peripheral blood sample.

26. (canceled)

27. (withdrawn) The method of claim 25, further comprising the step, after said lysing step and before said detecting step, of removing lysis debris.

28-38. (canceled)

39. (currently amended) A composition for flow cytometric measurement of a cell-surface molecule on human peripheral blood cells, wherein said cell-surface molecule is characterized in that a fluorescent signal measured following staining with a fluorescently labeled antibody specific for said cell-surface molecule in the absence of a lysosomotropic amine depends on the time of incubation with said antibody, said composition comprising:

a fluorophore-conjugated antibody specific for said cell-surface molecule, and a lysosomotropic amine.

40. (original) The composition of claim 39, wherein said lysosomotropic amine is selected from the group consisting of chloroquine, hydroxychloroquine, primaquine, and methylamine.

41. (original) The composition of claim 40, wherein said lysosomotropic amine is chloroquine.

42. (original) The composition of claim 40, wherein said lysosomotropic amine is hydroxychloroquine.

43. (original) The composition of claim 39, wherein said fluorophore is PE.

44. (original) The composition of claim 43, wherein said PE fluorophore and said antibody are conjugated at a defined molar ratio.

45. (original) The composition of claim 44, wherein said ratio is 1:1.

46-50. (canceled)

51. (previously presented) A kit for flow cytometric measurement of a cell-surface molecule on the surface of peripheral blood cells, comprising:  
a composition according to claim 39, and  
an erythrocyte lysing composition.

52-53. (canceled)

54. (original) The kit according to claim 51, further comprising: pelletized beads conjugated with defined levels of PE.

55-65. (canceled)